Compound Labs / United States
Empower Pharmacy
Compounding pharmacy in Houston, Texas, United States. Listed, not endorsed.
Peptides Empower Pharmacy names publicly
GHK-Cu (topical), Sermorelin, Gonadorelin, Semaglutide with B12, Tirzepatide combinations
Named on its own peptides page.
Licence and status, as stated
Operates a 503A pharmacy and a 503B outsourcing facility, and says it is registered with the FDA as a 503B and accredited by PCAB (company claims).
Who it supplies
503A: patients with a prescription. 503B: hospitals, medical offices and pharmacies.
Sourcing and testing, as stated
Sourcing: "USP quality ingredients from FDA-registered sources", as stated.
Testing: 503B: in-house assay, pH, particulate, endotoxin and sterility testing. 503A: third-party testing and stability studies. As stated.
These are the pharmacy's own statements. No results are published.
Public regulator records
- 2026-09-18: FDA warning letter to the 503A pharmacy, citing GLP-1 products the FDA calls "essentially copies" of approved drugs and insanitary conditions. Source
- 2025-04-02: FDA warning letter to the 503B facility. Source
- 2017-2021: Earlier FDA warning letters were issued in 2017, 2018 and 2021.
Stated as dated public records. They are not a judgement of the pharmacy today.
The rules in the United States
A 503A pharmacy compounds against a prescription for a named patient and is regulated by its state pharmacy board. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice (cGMP) and can supply clinics with stock for use in the office. Several firms hold both. The wellness peptides on this page (sermorelin, GHK-Cu, gonadorelin) come from the 503A side of those firms.
Whether a substance can be compounded at all depends on the FDA's bulk drug substances lists. Ipamorelin, GHRP-2, GHRP-6 and kisspeptin-10 remain on the FDA's Category 2 list of substances that may present significant safety risks. Nominations for BPC-157, TB-500, CJC-1295, GHK-Cu, thymosin alpha-1 and others were withdrawn, and the FDA page was last updated on 22 April 2026. A withdrawn nomination does not make a substance approved.
On 23 and 24 July 2026 an FDA advisory committee voted to add six peptides, including BPC-157, to the 503A bulks list. Those votes are not binding until the FDA completes rulemaking. Compounding of GLP-1 drugs on shortage grounds ended in 2025, and the FDA now pursues compounded products that are "essentially copies" of approved drugs.